According to a new market report published by Lucintel, the future of the biotherapeutics cell line development market looks promising with opportunities in bioproduction, tissue engineering & regenerative medicine, toxicity testing, research, and drug discovery applications. The global biotherapeutics cell line development market is expected to grow with a CAGR of 7% from 2020 to 2025. The major drivers for this market are increase in geriatric population and prevalence of diseases, government initiatives to boost biotechnology & pharmaceutical sectors, and development of advanced technologies to cater to the rising demand for monoclonal antibodies.
To download report brochure, please go to https://www.lucintel.com/biotherapeutics-cell-line-development-market.aspx and click "download brochure" tab from the menu
Biotherapeutics cell line development is a development of cell line expression systems to produce biologic medicines, which is complex, multi-stage, and time consuming, requiring specific expertise and access to suitable technologies. In this market, transfection & selection and single cell cloning are the major process segments. Lucintel forecasts that single cell cloning will remain the largest process segment over the forecast period due to rise in demand for biotherapeutics, increase in adoption of instruments, such as FACS (Fluorescence-Activated Cell Sorting) & ClonePix, and higher throughput nature of this method.
Within this market, outsource will remain the largest CLD option segment over the forecast period. The increase in demand for outsourced products, cost saving, and rapid delivery of products are some of the major factors that drive the outsource segment.
North America will remain the largest region over the forecast period due to high funding in new biological drugs, rise in geriatric population, increase in prevalence of various diseases in the developed countries of the region, and growth in government funding for research and development activities.
Merck KGaA, Becton, Dickinson and Company (BD), Danaher, Boehringer Ingelheim Group, Thermo Fisher Scientific, Lonza Group, Probiogen, Solentim, Selexis, and Sysmex are among the major suppliers in the global biotherapeutics cell line development market.
Lucintel, a leading global strategic consulting and market research firm, has analyzed growth opportunities in the global biotherapeutics cell line development market by process, CLD option, and region. Lucintel has prepared a comprehensive research report titled “Growth Opportunities in the Global Biotherapeutics Cell Line Development Market 2020-2025: Trends, Forecast, and Opportunity Analysis.” This Lucintel report serves as a catalyst for growth strategy, as it provides comprehensive data and analysis on trends, key drivers, and directions. The study includes trends and forecast for the global biotherapeutics cell line development market by process, CLD option, and region as follows:
By Process [Value ($ Million) shipment analysis for 2014 – 2025]:
Transfection & Selection and Single Cell Cloning
Consumable
By CLD Option [Value ($ Million) shipment analysis for 2014 – 2025]:
In-House
Outsourced
Do-It-Yourself
Hybrid
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
United States
Canada
Mexico
United Kingdom
Germany
Spain
Italy
France
This more than 150-page research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or visit us at helpdesk@lucintel.com.
About Lucintel
Lucintel, the premier global Management Consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, Growth Consulting, M&A, and Due diligence services to executives and key decision makers in a variety of industries. For further information, visit www.lucintel.com.